Sort by
Refine Your Search
-
, and scholarly activities. In partnership with Northeastern University, Dompé is offering a two-year fellowship in Global Medical Affairs - Real-World Evidence & Health Economics and Outcomes Research
-
inform our development programs. In this way, our Regulatory Affairs teams are transforming exciting science into valued new medicines for patients around the world. Strategic thinking is key within our
-
Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best
-
organization. The Fellow will contribute to meaningful projects that connect science, strategy, and patient needs, while developing the skills and perspective needed to build a career in Medical Affairs. In
-
Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best
-
employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine’s Top
-
/Biostatistics, Real-world Evidence Research, etc. is a plus Advanced degree (PhD/MS/MPH) in related fields like health economics and outcomes research, epidemiology, or public health is preferred Excellent oral
-
Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best
-
extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine’s Top Biopharma Employers, one of America's
-
Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best